Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib.

Date publication

août 2017

Journal

British journal of cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier

Tous les auteurs :
Joensuu H, Blay JY, Comandone A, Martin-Broto J, Fumagalli E, Grignani G, Del Muro XG, Adenis A, Valverde C, Pousa AL, Bouché O, Italiano A, Bauer S, Barone C, Weiss C, Crippa S, Camozzi M, Castellana R, Le Cesne A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28850565

Résumé

This multicentre phase II trial (DOVIGIST) evaluated the antitumour activity of dovitinib as second-line treatment of patients with gastrointestinal stromal tumour (GIST) refractory to imatinib or who do not tolerate imatinib.

Mots clés

Adult, Aged, Benzimidazoles, pharmacology, Biomarkers, Tumor, metabolism, Drug Resistance, Neoplasm, drug effects, Female, Follow-Up Studies, Gastrointestinal Neoplasms, drug therapy, Gastrointestinal Stromal Tumors, drug therapy, Humans, Imatinib Mesylate, pharmacology, Male, Middle Aged, Neoplasm Staging, Prognosis, Protein Kinase Inhibitors, pharmacology, Quinolones, pharmacology, Salvage Therapy

Référence

Br. J. Cancer. 2017 Aug;: